What's new

Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised

Feb 12, 2025 - 16:46
 0
Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised
Read More

Tags:

Previous Article

AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial

Next Article

FERC approves PJM’s fast-track power plant interconnection plan

Related Posts

Orphan designation: Allogenic umbilical cord-derived osteoblast cells Treatment of non-traumatic osteonecrosis, 16/01/2025 Positive

Orphan designation: Allogenic umbilical cord-derived os...

Feb 20, 2025  0

Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Date of authorisation: 11/02/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025  0

PRAC recommendations on signals adopted at the 10-13 Ma...

Apr 7, 2025  0